OBJECTIVE: To evaluate characteristics of unimpaired outcome in extremely low-birth-weight (ELBW) survivors. STUDY DESIGN: ELBW infants (n ¼ 714) with 30 months' assessments were analyzed. Logistic regression was used to develop a model for the binary outcome of unimpaired versus impaired outcome. RESULT: Thirty-three percent of infants had an unimpaired outcome. Seventeen percent of ELBW survivors had a Bayley II Mental Developmental Index score of X101 and 2% had a score of X116. Female gender, use of antenatal steroids (ANS), maternal education Xhigh school and the absence of major neonatal morbidities were independent predictors of unimpaired outcome. The likelihood of an unimpaired outcome in the presence of major neonatal morbidities was higher in infants exposed to ANS. CONCLUSION: The majority of unimpaired ELBW survivors had cognitive scores shifted toward the lower end of the normal distribution. Exposure to ANS was associated with higher likelihood of an unimpaired outcome in infants with major neonatal morbidities.
INTRODUCTION
Nearly 12% of all infants are born preterm in the United States each year and the proportion of live births with birth weight p1000 g (extremely low-birth-weight (ELBW) infants) has increased gradually over the last three decades. 1 Over this same period, advances in obstetric and neonatal care have improved the survival rate of these infants, which is currently B70%. [2] [3] [4] Rates of neurodevelopmental impairments in ELBW survivors remain high and concerns about their outcome persist into school age and adolescence. 4, 5 The majority of previous studies have primarily focused on the rates and predictors of impaired outcome, and there is only limited information available on factors associated with unimpaired outcome of these infants. The primary objective of this study was to determine the unimpaired survival rate among ELBW infants and to compare the associated perinatal, neonatal and socio-environmental characteristics of unimpaired outcome with infants having impairments at 30-monthcorrected age (CA). The secondary outcomes were to evaluate the Mental Developmental Index (MDI) score distribution of unimpaired ELBW survivors, and to evaluate concordance of outcome at 18 months and 30 months in ELBW infants. We hypothesized that unimpaired survival for ELBW infants at 30 months' CA would be associated with fewer neonatal morbidities and the distribution of the MDI scores of unimpaired survivors would be similar to the bell curve distribution expected in normal infants born at term gestation.
METHODS

Study population
The study subjects were derived from the original cohort of 1433 infants enrolled in the Glutamine Trial of the National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) between October 1999 and August 2001. 6 The institutional review board at each center approved the study protocol, and written, informed consent was obtained from a parent of each infant. The Glutamine study cohort is the only NICHD NRN cohort that has detailed neurodevelopmental outcome data available at 18 and 30 months of CA.
Data collection and infant evaluation
Clinical data including demographic data, obstetric care and neonatal morbidities during the initial hospitalization as well as post-neonatal hospitalizations were evaluated. Social and economic status information including maternal education and occupation, marital status, insurance status, income level and a detailed interim medical history, including data on hearing and vision status, were also reviewed. The ethnicity data is based on the maternal report of her own ethnicity. All infants born to mothers with partial or a complete course of antenatal steroids (ANS) were considered together for all statistical analysis. The following morbidities were considered major for the purpose of this study: bronchopulmonary dysplasia that was defined as the need for supplemental oxygen at 36 weeks, surgical necrotizing enterocolitis, grade III or grade IV intracranial hemorrhage and/or cystic periventricular leukomalacia, retinopathy of prematurity requiring laser therapy and any culture-proven late-onset sepsis and/or meningitis.
The details of follow-up examinations and the definitions of neurosensory impairments in this cohort of infants have been previously published by Vohr et al. classified as having mildly abnormal outcome if they had any of the following: MDI or Psychomotor Developmental Index scores between 70 and 84, mild CP, other mild neurological findings such as hypotonia, or minor sensory impairments such as need for glasses, transient conductive hearing loss, unilateral hearing loss or unilateral blindness. Moderate-to-severely abnormal outcome was defined as any of the following: MDI or Psychomotor Developmental Index scores of o70, moderate/severe CP, bilateral blindness or bilateral hearing loss requiring amplification.
Statistical analyses
The three primary study groups were infants who had: no impairment, mild impairment, and moderate-to-severe impairment. Preliminary analysis was performed to evaluate maternal characteristics and neonatal factors across the three-level unimpaired/impaired outcome. Categorical factors were evaluated by w 2 -tests. Continuous factors were evaluated using Kruskal-Wallis tests (based on ranked data). Logistic regression was used to analyze a fully specified model for the binary outcome: 1 ¼ unimpaired, 0 ¼ mildly or moderate-to-severely impaired. Duplicated and correlated factors, and factors that did not contribute to the model, were eliminated. Odds ratios (OR) and their 95% confidence intervals were obtained from the logistic regression. These OR were adjusted for the following covariates: center, gestational age, gender, race, singleton birth, marital status, mother's level of education, Medicaid/insurance status, english as a primary language, daily volume of human milk per kilogram body weight, ANS and major morbidity.
RESULTS
A total of 1433 infants were enrolled in the Glutamine trial and 1182 infants were discharged home. Twenty-two infants died after discharge but before 18-month follow-up. Out of 1160 infants eligible for the follow-up at 18 months, 169 infants were either lost to follow-up or had incomplete evaluation, and the complete outcome data at 18 months was available for 991 (85%) infants. Three network centers (217 infants) did not participate after 18-month follow-up, thus leaving a maximum of 943 infants eligible for the follow-up at 30 months. Four of these infants died between 18 and 30 months and 225 were either lost to follow-up or had incomplete evaluation. Thus, complete outcome data at 30 months was available for 714 (76%) of the 943 eligible infants.
Neurodevelopmental outcome and factors associated with unimpaired outcome Table 1 summarizes the neurodevelopmental outcome at 30-month CA. Thirty-three percent of all ELBW survivors had an unimpaired outcome, another one-third of all infants (34%) were mildly impaired and 238 (33%) had moderate-to-severe impairment. Maternal and infant characteristics of the cohort evaluated at 30 months are shown in Table 2 . After logistic regression analyses adjusted for covariates, female gender, use of ANS, maternal education Xhigh school diploma, breast milk intake and absence of major morbidity were significantly associated with unimpaired outcome (Table 3) . Combination of two factors, the use of ANS in the mother and the level of major morbidities significantly influenced the likelihood of an unimpaired outcome. Owing to the interaction between these two factors, OR for either one can only be stated at some specified level of the other factor. The presence of one or more major morbidity significantly reduced the odds of being unimpaired in infants not exposed to ANS. The exposure to ANS had no influence on the odds of unimpaired outcome in the absence of a major morbidity (0.93; 0.4 to 2.2, P ¼ 0.9) but improved the odds of being unimpaired in presence of one major morbidity (OR, 5.9; 1.7 to 20.9, P ¼ 0.006) or two or more major morbidities (OR, 3.5; 0.995 to 12.6, P ¼ 0.05) ( Table 4 ). Maternal race, age and insurance status did not significantly influence the outcome of these infants ( Table 3) .
Distribution of MDI scores
Thirty percent of all survivors and 57% of all unimpaired survivors had their MDI scores in the range of 85-100 (Table 1) . Only 2% of all survivors (7% of unimpaired survivors and none of the survivors in mild and moderate-to-severe impairment groups) had an MDI score of X116 ( Table 1 ). The MDI scores of ELBW survivors were shifted toward the lower end of normal distribution of scores on the bell curve for Bayley scores, only 17% of all ELBW survivors had an MDI score of X101, whereas a rate of 50% would be expected in this score range among a normal term cohort (Table 1) .
Neonatal morbidities and neurodevelopmental outcome Table 5 summarizes the rates of common neonatal morbidities in study infants. Thirty percent of all ELBW survivors were discharged with no major neonatal morbidity, and 45% of these infants were unimpaired as compared with 36% of infants with one major morbidity and 20% of infants with two or more major morbidities. Infants with one major morbidity were at least three times more likely to have cerebral palsy (CP) compared with infants with no major morbidities, and, using this same comparison group, infants with two or more major morbidities were almost six times more likely to have CP. Unimpaired outcome of extremely low-birth-weight survivors P Kumar et al
DISCUSSION
The reported incidence of unimpaired neurodevelopmental outcome in ELBW infants varies from 29.5 to 71%. 5, [8] [9] [10] Some of these differences can be attributed to different resuscitation practices at the threshold of viability, differences in perinatal characteristics such as use of ANS, neonatal practices such as use of postnatal steroids, different rates of neonatal morbidities, differences in assessment protocols and the duration of follow-up as well as the definitions used to define unimpaired outcome. Nearly one-third of all ELBW survivors in this study had unimpaired outcome at 30 months' CA, and this rate of unimpaired outcome is very similar to the rates previously reported by investigators using the similar assessment protocols and definitions, as used in this study. 5, 11 The rate of severe impairment in our cohort was also similar to the severe disability rate reported by Mercier et al.
12 based on 18 to 24 months' CA outcome data from 33 centers participating in Vermont Oxford Network; however, the rate of unimpaired outcome was not reported. Biological factors (female gender), environmental factors (maternal education Xhigh school diploma), medical practices (use of ANS), breast milk intake and the absence of a major morbidity were all highly associated with an unimpaired outcome in our cohort. Gender and maternal education have been previously reported to have a significant association with Unimpaired outcome of extremely low-birth-weight survivors P Kumar et al neurodevelopmental outcome of infants born preterm. [13] [14] [15] [16] Although the exact mechanisms explaining the higher rates of intact survival and better long-term outcomes in girls are unclear, it has been speculated that the immature fetal brain is more vulnerable in boys. 13, 14 The beneficial impact of mothers' education on neurodevelopmental outcome of preterm infants is multifactorial and supports the hypothesis that cognitive development is a complex process that can be influenced by mother's education and socioeconomic status. The beneficial effects of breast milk in this cohort of infants was published by Vohr et al. 7 They reported that increased ingestion of breast milk was associated with higher MDI scores, higher Bayley behavior score percentiles for emotional regulation and fewer rehospitalizations between discharge and 30 months. It was estimated that for every 10 ml kg À 1 per day increase in breast milk, the MDI increased by 0.59 points, the Psychomotor Developmental Index by 0.56 points and the total behavior percentile score by 0.99 points, and the risk of rehospitalization between discharge and 30 months decreased by 5%. 7 The previous studies have only reported the proportion of all infants or survivors with MDI scores X85, and to the best of our knowledge none of these studies further analyzed the distribution of MDI scores, a measure of cognitive function, among unimpaired survivors. The relationship between cognitive function and socioeconomic success has been the source of numerous studies and is highly controversial. The meta-analyses of the previous studies have shown that cognitive function is an important predictor of success, and later mortality risk. 17, 18 A closer look at the distribution of MDI score of unimpaired ELBW survivors in our cohort revealed that these infants had a significantly higher likelihood of having an MDI score in the lower range of the normal. Likelihood of a normal outcome is an important piece of information discussed during parental counseling, and the possibility of a normal outcome is frequently perceived by the parents that these infants will have the same potential for the cognitive achievement as their other normal siblings. The results of this study would suggest that this assumption may not be correct and unimpaired ELBW survivors are more likely to have cognitive function toward the lower end of the normal, and it is important to determine whether these infants can benefit from any early interventions. Our results could also potentially explain the findings of several recent reports on high rates of learning problems and poor academic achievements in children born very preterm and extremely preterm. 3, 4, 19, 20 Neonatal morbidity and unimpaired neurodevelopmental outcome Nearly one-third of our ELBW survivors had no major morbidity at discharge, which is comparable to the reports from other cohorts of ELBW infants. 12, 21 An adverse impact of different neonatal morbidities on subsequent neurodevelopmental outcome is well reported. Schmidt et al. 22 evaluated the prognostic effects of bronchopulmonary dysplasia, ultrasonographical signs of brain injury and severe retinopathy of prematurity on 18-month outcomes of ELBW infants, and reported that having one of the three morbidities doubled the risk of a poor outcome and having two morbidities approximately tripled the risk. Subsequently, they reported that infection and necrotizing enterocolitis added independent prognostic information to the previously reported morbidity-count model, but were weaker predictors of poor outcome than the previously evaluated three morbidities. 23 Although the observed rate of significant impairment in our cohort was similar to these previous reports (35 vs 33%), the adverse impact of the presence of either one or two or more neonatal morbidities was not as pronounced as in the previous studies. Some of the observed differences in the prognostic value of neonatal morbidities on the rate of neurosensory impairments could be related to the differences in the definitions of major morbidities and neurosensory impairments, differences in the duration of follow-up, environmental factors such as early intervention as well as different study populations but do suggest that a simple count of major morbidities may not be an as accurate a predictor of subsequent adverse neurodevelopmental outcome of all ELBW survivors as previously reported. These observations warrant further evaluation.
ANS and unimpaired neurodevelopmental outcome
The beneficial effects of ANS on neonatal survival and morbidities have been confirmed by several studies. However, the impact of ANS therapy on the neurological outcome including the risk of developing CP, cognitive and/or behavioral difficulties has not been studied well. A large European study recently reported that ANS therapy increased survival and decreased the rates of white matter injury in preterm infants born between 24 and 32 weeks of gestation, but had no effect on neurodevelopmental and behavioral outcome at 5 years. 24 In contrast, Carlo et al. 25 from the NICHD NRN recently reported that in a large cohort of extremely preterm infants, born between 22 and 25 weeks Unimpaired outcome of extremely low-birth-weight survivors P Kumar et al gestational age, ANS exposure was associated with a lower risk of both CP and neurodevelopmental impairment at 18 to 22 months. Although it is commonly assumed that the beneficial effect of ANS on neurodevelopmental outcome in ELBW infants is mediated by reduction in the likelihood of neonatal morbidities, in our cohort of ELBW survivors, use of ANS was associated with higher odds of unimpaired outcome in infants with one or more major morbidities. To the best of our knowledge, the impact of exposure to ANS on neurodevelopmental outcome of ELBW survivors in the presence or absence of major neonatal morbidities has not been studied before and warrants further study. This study has limitations. First, although we have a large sample size with prospectively collected data based on standardized protocols for data collection and evaluation by trained examiners, there are inherent weaknesses of a post hoc analysis. Second, nearly a quarter of all survivors did not have a 30-month evaluation. Although race and insurance status were not independent predictors of outcome in this cohort, we had a disproportionately larger number of non-white infants with public insurance, and the results of this study may not be applicable to other cohorts with a different patient mix. These limitations emphasize the need for additional studies to fully understand the cognitive potential and factors affecting the unimpaired outcome of ELBW survivors.
In summary, 33% of all ELBW survivors had unimpaired outcome at 30 months. However, the distribution of MDI scores of unimpaired survivors were skewed toward the lower end of normal, suggesting that the majority of ELBW survivors with normal cognitive outcome at 30 months' CA remained at a disadvantage compared with a normative population. Many diverse factors including biological and environmental factors, medical practices and absence or presence of a major neonatal morbidity influenced outcome. The use of ANS and the absence of major morbidities were significantly associated with unimpaired outcome. Although the presence of major morbidities was an important risk factor for future neurosensory impairment, the impact of major morbidities on long-term outcome, especially in infants exposed to ANS, requires further study. Unimpaired outcome of extremely low-birth-weight survivors P Kumar et al
